Herbalife (HLF) Kendi Hırpalanmış STOKUNA 250 Milyon $ Bahis Yaptı

Herbalife (HLF) Bets $250M On Its Own Battered Stock

Tue, September 15, 2026 at 12:51 PM GMT+3 4 min read

• HLF +0.25%

On September 8, Herbalife Ltd. (NYSE:HLF) told investors its board had cleared a new $250 million share buyback, to be spread across the next three years. For a stock trading in the single digits with a battered balance sheet, that is a bold vote of confidence from management in its own shares.

Four Straight Quarters Of Growth

CFO John DeSimone framed the buyback as a reflection of the company's free cash flow generation and flexibility to invest in the business while still returning capital to shareholders. The numbers back up part of that story. Herbalife's second quarter, reported August 5, brought net sales of $1.3 billion, up 5.4% year over year and at the top of guidance. Strip out currency swings and growth came in at 5.8%, marking the fourth straight quarter of year-over-year sales expansion on both a reported and constant currency basis. Latin America led the way, with net sales climbing 16.6%, while Asia Pacific jumped 15.2% and an even stronger 23.1% once currency effects are removed.

Adjusted EBITDA of $166.6 million landed near the top of the guided range, and on a constant currency basis it beat guidance outright at $174.4 million. Herbalife is also pushing into personalized nutrition, launching Bioniq GO across eleven European markets and the US in June and July, alongside new products under its Life I/O brand and an early beta of at-home blood biomarker diagnostics tied to its Pro2col platform. More than 110,000 people attended the company's 2026 Extravaganza events, a sign that its distributor network is still showing up.

A Balance Sheet Still Underwater

The same quarter that produced the growth numbers also produced a net loss. Herbalife posted a net loss attributable to the company of $26.3 million, driven largely by a $94.6 million charge tied to extinguishing debt after an April refinancing. Gross margin slipped to 77.7% from 78.0% a year earlier, and adjusted EBITDA margin fell 120 basis points to 12.6%. Not every region is growing either. China sales dropped 24.5% as reported and 29.0% at constant currency, while EMEA fell 3.5%, or 5.6% adjusting for currency.

Management responded by narrowing full-year 2026 guidance, trimming the reported adjusted EBITDA range to $670 million to $690 million from a prior $675 million to $705 million, citing FX headwinds even as the constant currency outlook was actually raised. Leadership is also in flux. DeSimone, the CFO championing the buyback, is set to retire at the end of 2026, handing the role to Scott Schaefer on January 1, 2027. And the balance sheet itself remains a concern: Herbalife carried a total shareholders' deficit of $466.9 million as of June 30, alongside more than $2 billion in long-term debt.

A Stock Priced For Skepticism

Hedge fund ownership of Herbalife fell from 38 funds to 34 in the most recent quarter, which points to institutional money trimming rather than adding. Short interest sits at 9.72% of float, high enough to reflect a real bear camp rather than routine hedging. Meanwhile, the stock trades at a forward P/E of just 3.88, as of September 14, a multiple that implies the market is pricing in serious doubts about the durability of those earnings. That combination is not the profile of a stock the market is betting on. It is the profile of one Wall Street has largely written off, buyback or not.

Two Stories, One Stock

Herbalife's own management is putting real money behind the belief that shares are undervalued, backed by four consecutive quarters of sales growth and cash flow strong enough to fund both reinvestment and repurchases. But the market has responded with departing hedge funds, elevated short interest, and a multiple that assumes trouble ahead. For the buyback thesis to pay off, the constant currency growth and margin discipline in markets like Latin America and Asia Pacific need to keep outrunning the FX drag and the China slide.

While we acknowledge the potential of HLF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.